Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How I treat myelofibrosis.

Blood - 23 Oct 2014

Cervantes Francisco

Abstract excerpt

Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm characterized by clonal myeloproliferation, dysregulated kinase signaling, and release of abnormal cytokines. In recent years, important progress has been made in the knowledge of the molecular biology and the prognostic assessment of MF. Conventional treatment has limited impact on the patients' survival; it includes a wait-and-see approach...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Janus Kinases
Share to Nitriles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Primary Myelofibrosis

Share to Pyrazoles

Share to Pyrrolidines

Share to Splenomegaly

Share to Stem Cell Transplantation

Source

Identifiers

PMID: 25232060
DOI: 10.1182/blood-2014-07-575373

Genes

JAK2
ABL1
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How I treat myelofibrosis.PMID 25232060Read ↗

Myelofibrosis: an update on current pharmacotherapy and future directions.Semantic proximity Read ↗

Management of Myelofibrosis: from Diagnosis to New Target Therapies.Semantic proximity Read ↗

How I treat myelofibrosis after failure of JAK inhibitors.Semantic proximity Read ↗

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives.Semantic proximity Read ↗

[Research Progress on Effect of JAK Inhibitors on Myelofibrosis- Review].Semantic proximity Read ↗

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and TreatmentsSemantic proximity Read ↗

Primary Myelofibrosis: Update on Definition, Pathogenesis, and TreatmentSemantic proximity Read ↗

The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication.Semantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?Semantic proximity Read ↗

Novel therapies for myelofibrosis.Semantic proximity Read ↗

How many JAK inhibitors in myelofibrosis?Semantic proximity Read ↗

Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.